Massachusetts-based Repligen Corporation, a life sciences company focused on bioprocessing technology leadership, has agreed to acquire BioLife Solutions, a leading developer and supplier of cell processing tools and services for cell and gene therapy, in a deal with a total enterprise value of approximately $1.5 billion, composed of 64 percent Repligen common stock and 36 percent cash. The deal is expected to close in the fourth quarter of 2026. Both Repligen and BioLife are traded on the NASDAQ.
To add details to this portfolio regarding legal or economic representatives, please contact editors@mlex.com